During the last session, Pyxis Oncology Inc (NASDAQ:PYXS)’s traded shares were 0.82 million, with the beta value of the company hitting 1.06. At the end of the trading day, the stock’s price was $1.32, reflecting an intraday gain of 1.54% or $0.02. The 52-week high for the PYXS share is $6.85, that puts it down -418.94 from that peak though still a striking 6.82% gain since the share price plummeted to a 52-week low of $1.23. The company’s market capitalization is $78.50M, and the average intraday trading volume over the past 10 days was 0.62 million shares, and the average trade volume was 1.30 million shares over the past three months.
Pyxis Oncology Inc (PYXS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.25. PYXS has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.33.
Pyxis Oncology Inc (NASDAQ:PYXS) trade information
Pyxis Oncology Inc (PYXS) registered a 1.54% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 1.54% in intraday trading to $1.32, hitting a weekly high. The stock’s 5-day price performance is -5.71%, and it has moved by -10.20% in 30 days. Based on these gigs, the overall price performance for the year is -71.86%. The short interest in Pyxis Oncology Inc (NASDAQ:PYXS) is 7.0 million shares and it means that shorts have 11.41 day(s) to cover.
The consensus price target of analysts on Wall Street is $7, which implies an increase of 81.14% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7 and $7 respectively. As a result, PYXS is trading at a discount of -430.3% off the target high and -430.3% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -118.72%. While earnings are projected to return 40.99% in 2025, the next five years will return 12.25% per annum.
PYXS Dividends
Pyxis Oncology Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Pyxis Oncology Inc (NASDAQ:PYXS)’s Major holders
Pyxis Oncology Inc insiders own 24.57% of total outstanding shares while institutional holders control 58.45%, with the float percentage being 77.49%. DEEP TRACK CAPITAL, LP is the largest shareholder of the company, while 132.0 institutions own stock in it. As of 2024-06-30, the company held over 4.18 million shares (or 8.1578% of all shares), a total value of $13.85 million in shares.
The next largest institutional holding, with 3.86 million shares, is of LAURION CAPITAL MANAGEMENT LP’s that is approximately 7.5282% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $12.78 million.
Also, the Mutual Funds coming in first place with the largest holdings of Pyxis Oncology Inc (PYXS) shares are iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund . Data provided on Nov 30, 2024 indicates that iShares Russell 2000 ETF owns about 1.34 shares. This amounts to just over 2.25 percent of the company’s overall shares, with a $1.76 million market value. The same data shows that the other fund manager holds slightly less at 1.29, or about 2.18% of the stock, which is worth about $1.71 million.
